Changzhou Qianhong Biopharma CO.,LTD (002550.SZ)
CNY 5.7
(0.18%)
CNY 5.7
(0.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 278.66 Million CNY | -41.88% |
| 2022 | 442.64 Million CNY | 70.6% |
| 2021 | 281.45 Million CNY | -23.08% |
| 2020 | -75.34 Million CNY | -29.74% |
| 2019 | 366.49 Million CNY | 23.13% |
| 2018 | 336.64 Million CNY | 16.2% |
| 2017 | 293.53 Million CNY | -5.43% |
| 2016 | 308.61 Million CNY | -6.62% |
| 2015 | 323.53 Million CNY | 7.58% |
| 2014 | 309.15 Million CNY | 28.15% |
| 2013 | 238.49 Million CNY | 15.13% |
| 2012 | 205.64 Million CNY | 7.41% |
| 2011 | 195.46 Million CNY | -0.59% |
| 2010 | 186.17 Million CNY | 17.39% |
| 2009 | 166.29 Million CNY | 32.59% |
| 2008 | 123.33 Million CNY | 108.38% |
| 2007 | 58.38 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 123.19 Million CNY | 2676.1% |
| 2024 Q3 | 142.45 Million CNY | 33.79% |
| 2024 Q2 | 100.1 Million CNY | -21.23% |
| 2023 FY | - CNY | -41.88% |
| 2023 Q2 | 34.25 Million CNY | -64.18% |
| 2023 Q1 | 95.63 Million CNY | 1364.1% |
| 2023 Q4 | -15.99 Million CNY | -120.67% |
| 2023 Q3 | 77.34 Million CNY | 125.8% |
| 2022 FY | - CNY | 70.6% |
| 2022 Q3 | 67.13 Million CNY | -23.25% |
| 2022 Q2 | 87.47 Million CNY | -46.12% |
| 2022 Q1 | 162.35 Million CNY | 2092.43% |
| 2022 Q4 | 6.53 Million CNY | -90.27% |
| 2021 Q4 | -8.14 Million CNY | -113.98% |
| 2021 Q1 | 72.41 Million CNY | 73.01% |
| 2021 Q3 | 58.29 Million CNY | 63.76% |
| 2021 FY | - CNY | -23.08% |
| 2021 Q2 | 35.59 Million CNY | -50.85% |
| 2020 Q4 | 41.85 Million CNY | -57.02% |
| 2020 Q3 | 97.38 Million CNY | -2.32% |
| 2020 Q2 | 99.69 Million CNY | 849.07% |
| 2020 FY | - CNY | -29.74% |
| 2020 Q1 | -13.3 Million CNY | -118.41% |
| 2019 Q1 | 110.45 Million CNY | 2016.26% |
| 2019 FY | - CNY | 23.13% |
| 2019 Q4 | 72.3 Million CNY | 18.47% |
| 2019 Q3 | 61.03 Million CNY | -45.42% |
| 2019 Q2 | 111.82 Million CNY | 1.24% |
| 2018 Q1 | 91.38 Million CNY | -6.75% |
| 2018 FY | - CNY | 16.2% |
| 2018 Q4 | 5.21 Million CNY | -91.99% |
| 2018 Q3 | 65.12 Million CNY | -45.33% |
| 2018 Q2 | 119.12 Million CNY | 30.36% |
| 2017 Q3 | 4.49 Million CNY | -96.29% |
| 2017 Q1 | 61.24 Million CNY | -58.29% |
| 2017 FY | - CNY | -5.43% |
| 2017 Q2 | 120.89 Million CNY | 97.41% |
| 2017 Q4 | 97.99 Million CNY | 2082.31% |
| 2016 FY | - CNY | -6.62% |
| 2016 Q1 | 47.48 Million CNY | -68.3% |
| 2016 Q3 | 19.34 Million CNY | -85.23% |
| 2016 Q2 | 131.01 Million CNY | 175.91% |
| 2016 Q4 | 146.81 Million CNY | 658.82% |
| 2015 Q2 | 114.66 Million CNY | 158.22% |
| 2015 FY | - CNY | 7.58% |
| 2015 Q4 | 149.79 Million CNY | 183.06% |
| 2015 Q3 | 52.92 Million CNY | -53.85% |
| 2015 Q1 | 44.4 Million CNY | -71.38% |
| 2014 Q2 | 84.33 Million CNY | 123.16% |
| 2014 Q4 | 155.17 Million CNY | 197.52% |
| 2014 FY | - CNY | 28.15% |
| 2014 Q1 | 37.79 Million CNY | -66.36% |
| 2014 Q3 | 52.15 Million CNY | -38.16% |
| 2013 Q2 | 65.58 Million CNY | 71.79% |
| 2013 Q3 | 37.99 Million CNY | -42.07% |
| 2013 Q4 | 112.33 Million CNY | 195.67% |
| 2013 FY | - CNY | 15.13% |
| 2013 Q1 | 38.17 Million CNY | -60.13% |
| 2012 Q2 | 42.36 Million CNY | 66.9% |
| 2012 Q3 | 29.29 Million CNY | -30.85% |
| 2012 Q1 | 25.38 Million CNY | -65.84% |
| 2012 FY | - CNY | 7.41% |
| 2012 Q4 | 95.73 Million CNY | 226.82% |
| 2011 FY | - CNY | -0.59% |
| 2011 Q2 | 49.24 Million CNY | 10.4% |
| 2011 Q1 | 44.6 Million CNY | -17.37% |
| 2011 Q3 | 24.56 Million CNY | -50.13% |
| 2011 Q4 | 74.31 Million CNY | 202.55% |
| 2010 Q3 | 30.52 Million CNY | -24.23% |
| 2010 Q1 | 64.52 Million CNY | 53.28% |
| 2010 FY | - CNY | 17.39% |
| 2010 Q4 | 53.98 Million CNY | 76.84% |
| 2010 Q2 | 40.28 Million CNY | -37.56% |
| 2009 Q4 | 42.09 Million CNY | 52.62% |
| 2009 Q3 | 27.58 Million CNY | 0.0% |
| 2009 FY | - CNY | 32.59% |
| 2008 FY | - CNY | 108.38% |
| 2007 FY | - CNY | 0.0% |